Skip to main content
Premium Trial:

Request an Annual Quote

Atum, Horizon Discovery Sign Cross-Licensing Deal for Cell Line Production Tech

NEW YORK (GenomeWeb) – Atum and Horizon Discovery announced today that they have signed a cross-licensing agreement for their respective cell line production technologies.

Under the terms of the deal, Atum — formerly DNA2.0 — has been given a license to Horizon's CHO Source biomanufacturing platform, including the glutamine synthetase (GS) knockout CHO K1 line, which it will combine with its own Leap-In transposase technology as a cell line development service. Horizon, meanwhile, has been given an exclusive license to a vector suite developed by Atum for the CHO Source platform. Horizon customers will also be offered a no-fee evaluation license for the Leap-In system.

Additional terms were not disclosed.

"Horizon's GS line and Atum's vectors and transposase technology are a very powerful combination for production of stable cell lines," Atum Cofounder and CEO Jeremy Minshull said in a statement. "This technology is suited not just for regular antibodies, but for the next wave of biologics including two, three, and four-chain bispecifics, and require only small numbers of clones to be screened to reach commercial titers."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.